Loading…
Employees: 641
Size Oncology Institute (STLN) is a United States Health Care company (Medical/Nursing Services) with a market value of $362M, the 2947th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.62 on 6 Nov 2026.
Growth Revenue grew 38.4% over the last twelve months (peer median +6.0%); the operating margin is -4.4% (peer median 8.4%).
Valuation It trades at 0.7× enterprise value to sales against a peer median of 1.6× (2nd cheapest of 21).
Capital Return on invested capital runs 60.4 points below its cost of capital (6.8% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $587M | $503M | $393M | $324M | $252M |
| Revenue growth | — | +28% | +21% | +28% | — |
| Gross profit | $85.4M | $69.5M | $47.7M | $53.7M | $47.7M |
| EBITDA | -$19.3M | -$29.1M | -$53.8M | -$54.2M | -$66.8M |
| Net income | -$30.5M | -$50.3M | -$53.0M | -$67.9M | $132,000 |
| Free cash flow | -$3.29M | -$27.8M | -$30.3M | -$40.9M | -$67.3M |
| Capital expenditure | $3.61M | $3.20M | $3.79M | $4.57M | $5.53M |
| Total debt | $104M | $104M | $123M | $120M | $108M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STLN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -41.4% | -5.7% | lowest of 21 |
| Distance from 52-week high | -49.2% | -23.3% | 3rd lowest of 21 |
| Revenue growth (TTM) | +38.4% | +6.0% | 4th highest of 21 |
| Operating margin | -4.4% | 8.4% | 4th lowest of 21 |
| EV / Sales | 0.7× | 1.6× | 2nd cheapest of 21 |
| ROIC minus cost of capital | -60.4 pp | -1.0 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oncology Institute STLN | United States | $362M | n/a | +38% | -4% | 0.7× | n/a | n/a |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -2% | 0.4× | -15.1% | +9.6% |
| NIOX NIOX.L | United Kingdom | $349M | +2% | +3% | 22% | 5.1× | 3.9% | +15.3% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 1.2× | -5.5% | +17.9% |
| Auna AUNA | United States | $346M | -8% | +17% | 13% | 1.0× | -10.5% | +24.4% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | 6.2× | 22.4% | -5.8% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $324M | -7% | 0% | 31% | 2.6× | -12.3% | +15.4% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 1.3× | 12.0% | -1.5% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 1.3× | 3.9% | +2.6% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 4.7× | 8.1% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 1.5× | 8.3% | +17.7% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 1.6× | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | 2.7× | 8.8% | +3.2% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 5.8× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | 1.2× | n/a | n/a |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |